Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.55 |
| ▸ | TOP2A | P11388 | 2/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025308 | 1.00 | HKDC1 (0.55) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL29506909 | 0.91 | HKDC1 (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL881251 | 0.91 | HKDC1 (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL5839502 | 0.86 | TOP2A (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL29723632 | 0.86 | TOP2A (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL29882877 | 0.86 | TOP2A (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL17207742 | 0.86 | TOP2A (0.67) | HKDC1TOP2AAGTR1LMNARAB9A | |
| SCHEMBL12562236 | 0.86 | HKDC1 (0.46) | HKDC1TOP2AAGTR1RAB9AKDM4E | |
| SCHEMBL9938958 | 0.85 | HKDC1 (0.54) | HKDC1TOP2AAGTR1LMNARAB9A | |
| Hydrochloric Acid SCHEMBL9938465 | 0.84 | HKDC1 (0.53) | HKDC1TOP2AAGTR1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| CN-120077031-A | Prodrug kit for multitube concurrent chemotherapy | 亚历克斯·祖内克 | 2025-05-30 | — | — | CN | claimed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | claimed |
| CN-118453558-A | Use of iron chelators and their use in compositions with platinum compounds | 广东医科大学附属医院 | 2024-08-09 | — | — | CN | claimed |
| WO-2024008833-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2024-01-11 | — | — | WO | claimed |
| CN-116672457-A | Application of pharmaceutical composition in preparation of candida albicans resistant medicines | 上海市同济医院 | 2023-09-01 | — | — | CN | claimed |
| CN-116236481-A | Application of Dp44mT in preparation of anti-candida albicans drugs | 上海市同济医院 | 2023-06-09 | — | — | CN | claimed |
| WO-2023068423-A1 | COMPLEX ANTICANCER DRUG COMPOSITION USING PHOTOREACTIVITY AND PREPARATION METHOD THEREFOR | 닥터아이앤비(주) | 2023-04-27 | — | — | WO | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2022037594-A1 | USE OF IRON CHELATING AGENT IN PREPARATION OF DRUG FOR TREATING OR PREVENTING POLYOMAVIRUS INFECTION | 上海市公共卫生临床中心 | 2022-02-24 | — | — | WO | claimed |
| CN-114073772-A | Use of an iron chelator for the treatment or prevention of polyoma viral infections | 上海市公共卫生临床中心 | 2022-02-22 | — | — | CN | claimed |
| WO-2026086847-A1 | CYCLOPEPTIDE DRUG CONJUGATE AND USE THEREOF | 中山医诺维申新药研发有限公司 | 2026-04-30 | — | — | WO | disclosed |
| CN-116672457-B | Application of pharmaceutical composition in preparation of candida albicans resistant medicines | 上海市同济医院 | 2026-04-07 | — | — | CN | disclosed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| CN-114341158-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022063351-A1 | AZULENE HYDRAZIDE-HYDRAZONES AND THEIR USE IN THE TREATMENT OF ONCOLOGIC DISEASES | UNIVERZITA KARLOVA (CZ) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022037594-A1 | USE OF IRON CHELATING AGENT IN PREPARATION OF DRUG FOR TREATING OR PREVENTING POLYOMAVIRUS INFECTION | 上海市公共卫生临床中心 | 2022-02-24 | — | — | WO | disclosed |
| CN-114073772-A | Use of an iron chelator for the treatment or prevention of polyoma viral infections | 上海市公共卫生临床中心 | 2022-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | HKDC1 1037/4885TOP2A 299/4885AGTR1 3420/4885 |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | HKDC1 580/4885TOP2A 827/4885AGTR1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.